Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.
The presence of less studied HCV genotypes may compromise cure rates.
Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.
Researchers analyzed PPIs’ potential effects on nearly 2,400 participants of nine studies of Mavyret.
The U.S. FDA announced the approval of Mavyret, the first treatment for all hepatitis C genotypes in children ages 12 to 17.
The U.S. FDA approved hepatitis C treatment Mavyret for children from ages 12 to 17 with all genotypes.
The approval applies to those between 12 and 17 years old who have any of the six genotypes of the virus.
A quick overview of Hep Magazine’s reporting on the 53rd International Liver Congress in Vienna
These drugs are approved to treat all six major genotypes of hepatitis C.
This from a real-world analysis of people treated for hep C in the United States.
A study compared treatment outcomes among those seen at standard intervals with those seen for just two clinic visits.
A real-world study of AbbVie’s hep C regimen Mavyret (glecaprevir/pibrentasvir) included people often excluded from clinical trials.
Nearly all those who have completed follow-up in an ongoing Italian study have been cured.
These two men both recently discovered that they had hepatitis C, each with a different story about their encounters with insurance.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.